Comment on OMB-2026-0034-0001

Summary: Evan Friedmann, representing Hellma USA, Inc. and several scientific leadership roles, opposes the proposed rule because it prioritizes political alignment over merit-based science and introduces instability into research funding. He argues that the rule will stifle innovation, damage international scientific standards, and create bureaucratic hurdles that hinder the development of medical technologies and the dissemination of scientific research.